A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Renal TransplantationGraft Rejection
Interventions
DRUG

Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]

Trial Locations (19)

10029

Mount Sinai School of Medicine, New York

21287

Johns Hopkins University Hospital, Baltimore

23298

Medical College of Virginia, Richmond

27710

Duke University Medical Center, Durham

30322

Emory University, Atlanta

45219

Christ Hospital, Cincinnati

45267

University of Cincinnati Medical Center, Cincinnati

46202

Indiana University, Indianapolis

53226

Medical College of Wisconsin, Milwaukee

70121

Oschner Medical Center, New Orleans

72205

University of Arkansas for Medical Science, Little Rock

78229

Texas Transplant Institute, San Antonio

80262

University of Colorado Health Sciences Center, Denver

90033

Keck USC School of Medicine, Los Angeles

90095

University of California, Los Angeles Medical Center, Los Angeles

92103

University of California, San Diego Medical Center, San Diego

94115

California Pacific Medical Center, San Francisco

94143

University of California, San Francisco, San Francisco

07039

Saint Barnabas Medical Center, Livingston

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00089947 - A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection | Biotech Hunter | Biotech Hunter